Secondary hyperparathyroidism (SHPT) affects a majority of patients with chronic kidney
disease (CKD) of stage 3 or worse. Despite the development of calcimimetics and their …

In chronic kidney disease (CKD), hyperphosphatemia induces fibroblast growth factor-23
(FGF-23) expression that disturbs renal 1, 25-dihydroxy vitamin D (1, 25D) synthesis; …

Positive allosteric modulator (PAM) drugs enhance the activation of the calcium-sensing
receptor (CaSR) and suppress parathyroid hormone (PTH) secretion. Unfortunately, these …

Objectives Frailty can cause increased vulnerability to adverse health outcomes, such as
falls, fractures, depression and reduced health-related quality of life (HRQoL). This cross …

Secondary hyperparathyroidism (SHPT), the most common complication in the later stage of
chronic kidney disease (CKD), seriously affects quality of life and the survival time of …

BACKGROUND: Chronic kidney disease (CKD) is a structural or functional kidney disease
for more than 3 months. In predialysis CKD patients, the serum parathyroid hormone levels …

Drugs acting as positive allosteric modulators (PAMs) to enhance the activation of the
calcium sensing receptor (CaSR) and to suppress parathyroid hormone (PTH) secretion can …

Primary hyperparathyroidism (pHPT) afflicts our aging population with an incidence
approaching 50 per 100 000 patient-years at a female: male ratio of~ 3: 1. Decisions …

Background The aim of this study was to identify changes in gene expression before and
after 5-aminolevulinic acid-mediated photodynamic therapy (5-ALA-PDT) and to investigate …

Objective. Our study aimed to develop and validate a nomogram to predict severe
hypocalcemia (SH) before total parathyroidectomy (TPTX) without auto‐transplantation in …